Monthly Update: Biologicals & Immunologicals: Progress with humanised antibodies - An update

References

• EMERY SC, ADAIR JR: Humanized monoclonal antibod-ies for therapeutic applications. Exp. Opin. Invest. Drugs (1994) 3(3):241–251.
   Google Scholar
• FDC REPORTS, INC.: The Pink Sheet (February 27, 1995):T&G–5.
   Google Scholar
• SHALABY MR, SHEPARD HM, PRESTA L, RODRIGUES ML, BEVERLEY PCL, FELDMANN M, CARTER P: Development of humanized bispecific antibodies reactive with cyto-toxic lymphocytes and tumor cells overexpressing the HER2 protooncogene. J. Exp. Med. (1992) 175:217–225.
   PubMed Web of Science ®Google Scholar
• ADAIR JR, ATHWAL DS, BODMER MW, BRIGHT SM, COL-LINS AM, PULITO VL, RAO PE, REEDMAN R, ROTHERMEL AL, XU D, ZIVIN RA, JOLIFFE LK: Humanization of the murine anti-human CD3 monoclonal antibody OKT3. Hum. Antibod. Hybridomas (1994) 5:41–47.
   PubMedGoogle Scholar
• WRIGHT L: Bio/Technology (1994) 12:855.
   Google Scholar
• BioWorld Today (May 11, 1995).
   Google Scholar
• ANONYMOUS: Scrip (September 30, 1994).
   Google Scholar
• WARD M: Bio/Technology (1995) 13:425–426.
   Google Scholar
• BERNSTEIN K: BioCentury (July 3, 1995):3.
   Google Scholar
• FOX JL: Bio/Technology (1994) 12:14–15.
   Google Scholar
• CRAIG C: BioWorld Today (July 20, 1995) 6(138):1.
   Google Scholar
• FDC REPORTS, INC.: The Pink Sheet (May 29, 1995).
   Google Scholar
• SHRINE J: Bio World Today (April 14, 1995) 6(72):1.
   Google Scholar
• ANONYMOUS: scrip (May 10, 1995) 2026:27.
   Google Scholar
• CRAIG C: Bio World Today (June 9, 1995) 6(111):1.
   Google Scholar
• AULITZKY WE, SCHULZ TF, TILG H, NIEDERWIESER D, LARCHER K, OSTBERG L, SCRIBA M, MARTINDALE J, STERN AC, GRASS P, MACH M, DIERICH MP, HUBER C: Human monoclonal antibodies neutralizing cytomegalovirus (CMV) for prophylaxis of CMV disease: Report of a Phase I trial in bone marrow transplant recipients. J. Infect. Dis. (1991) 163:1344–1347.
   PubMed Web of Science ®Google Scholar
• CORNETT JB: Clinical results with humanized and hu-man monockmal antibodies. Animal Cell Biotechnology. Basic and Applied Aspects (1994) 6:63–73.
   Google Scholar
• HAMILTON A, KING S, ROY D, GRUNDY J, CARR F, HARRIS W: A reshaped antibody against human cytomega-lovirus gH for treatment and prophylaxis. Proceedings of the 4th International Cytomegalovirus Conference. Paris, France (1993).
   Google Scholar
• CARTER P, KELLEY RE, ROGRIGUES ML, SNEDCOR B, COVARRUBIAS M, VELLIGAN MD, WONG WET, ROWLAND AM, KOTTS CE, CARVER ME, YANG M, BOURELL JH, SHEPARD HM, HENNER D: High level Escbericlita coil expression and production of a bivalent humanized antibody fragment. Bio/Technology (1992) 10:163–167.
   PubMed Web of Science ®Google Scholar
• CARTER P: Personal communication.
   Google Scholar
• RODRIGUEZ ML, PRESTA LG, Korr's CE, WIRTH C, MOR- DENTI J, OSAKA G, WONG WLT, NUIJENS A, BLACKBURN B, CARTER P: Development of a humanized disulphide-stabilized anti-p185 HER2 Fv-3lactamase fusion protein for activation of a cephalosporin doxorubicln prodrug. Cancer Res. (1995) 55:63–70.
   PubMed Web of Science ®Google Scholar
• SHALABY MR, CARTER P, MANEVAL D, GILTINAN D, KOTTS C: Bispecific HFit2 x CD3 antibodies enhance T-cell cytotoxicity in vitro and localize to HER2-overex-pressing xenografts in nude mice. Clin. Immunol. Immu-nopath . (1995) 74:185–192.
   PubMedGoogle Scholar
• CELLTECH PLC: Annual Report (1994).
   Google Scholar
• CELLTECH PLC: Interim Report (1995).
   Google Scholar
• KING DJ, ANTONIW P, OWENS RJ, ADAIR JR, HAINES AMR, FARNSWORTH APH, FINNEY H, LAWSON ADG, LYONS A, BAKER TS, BALDOCK D, MACKINTOSH J, GOFTON C, YARRANTON GT, MCWILLIAMS W, SHOCHAT D, LEICHNER PK, WELT S, OLD LJ, MOUNTAIN A: Humanisation of monoclonal antibody A33 and preclinical evaluation of humanised A33 immunoconjugates for cancer therapy. (1995) In press.
   Google Scholar
• BioCentury (May 2, 1995) 3(39):10.
   Google Scholar
• MALONEY DG, LEES TM, CZERWINSKI DK, WALDICHUK C, ROSENBERG J, GRILLO-LOPEZ A, LEVY R: Phase I clinical trial using escalating single dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) In patients with recurrent B-cell lymphoma. Blood (1994) 84:2457–2465.
   PubMed Web of Science ®Google Scholar
• RANKIN ECC, CHOY EHS, KASSIMOS D, KINGSLEY GH, SOP WITH AM, ISENBERG DA, PANAYI GS: The therapeu-tic effects of an engineered human anti-tumour ne-crosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br. J. Rheumatol. (1995) 34:334–342.
   PubMedGoogle Scholar
• BAKER TS, BOSE CC, FINNEY HM, KING DJ, LAWSON ADG, LYONS AH, OWENS RJ, ROLFE MR, SEHDEV M, ADAIR JR: Humanization of an anti-mucin antibody for breast and ovarian cancer therapy. Im Antigen and Antibody Molecu-lar Engineering in Breast Cancer Diagnosis and Treatment. Ceriani RL (Ed.). Plenum Press, New York (1994):61–82.
   Google Scholar
• REFF M: High-level production of recombinant immu- noglobulins in inammalinn cells. Curr. opin. Biotech (1993) 4:573–576.
   PubMedGoogle Scholar
• ANONYMOUS: Genetic Engineering News (1995) 15(11):26.
   Google Scholar
• CRAWLEY P: Antibody patents. In: Monoclonal Antibodies: Principles and Applications. Birch JR, Lennox ES (Eds.). Wiley-Liss, Inc., New York (1994):299–335.
   Google Scholar
• ROGUSKA MA, PEDERSEN JT, KEDDY CA, HENRY AH,SEARLE SJ, LAMBERT JM, GOLDMACHER VS, BLATTLER WA, REES AR, GUILD BC: Humanization of murine mono-clonal antibodies through variable domain resurfacing. Proc. Natl. Acad. Sci. USA (1994) 91:969–973.
   PubMed Web of Science ®Google Scholar
• UN H, KRISTENSSON K, CRUZ G, GLASER S, ROSOK M. HARRIS L, HUSE WD: A novel method for humanization of monoclonal antibodies using codon based oligonu-cleotides. Fifth Annual IBC Conference Antibody Engineer-ing: New Technology, Application and Commercialization'. La Jolla, CA, USA. 1994.
   Google Scholar
• GLASER SM, YELTON DE, HUSE WD: Antibody engineer-ing by codon-based mutagenesis in a filamentous phage vector system. J. Immunol. (1992) 149:3903–3913.
   PubMed Web of Science ®Google Scholar
• GADINA M, NEWTON DL, RYBAK SM, NVU Y-N, YOULE RJ: Humanized immunotoxins. Therapeutic Immunology (1994) 1:59–64.
   PubMedGoogle Scholar
• BOSSLET K, CZECH J, HOFFMANN D: Tumor selective prodrug activation by fusion protein-mediated cataly-sis. Cancer Res. (1994) 54:2151–2159.
   PubMed Web of Science ®Google Scholar
• HUENNEICENS FM: Tumor targeting: activation of pro-drugs by enzyme-monoclonal antibody conjugates. 77B-TECH (1994) 12:234–239.
   Google Scholar
• BAGSHAWE KD, SHARMA SK, SPRINGER CJ, ANTONIW P: Antibody directed prodrug therapy: pilot scale clinical trial. Tumour Targeting (1995) 1:17–29.
   Google Scholar
• WANG Q, PAT L, DEBINSKI W, FITZGERALD DJ, PASTAN I: Polyethylene glycol modified chimeric toxin composed of transforming growth factor a and Pseudomonas exotoxin. Cancer Res. (1993) 53:4588–4594.
   PubMed Web of Science ®Google Scholar
• HODGSON CP: The vector void in gene therapy. Bio/Technology (1995) 13:222–225.
   PubMed Web of Science ®Google Scholar
• BIOCCA S, CATTANEO A: Intracellular immunization: antibody targeting to subcellular compartments. Trends in Cell Biology (1995) 5:248–252.
   PubMed Web of Science ®Google Scholar
• MAClEJEWSKI JP, WEICHOLD FF, YOUNG NS, CARA A, ZELLA D, REITZ MS, GALLO RC: Intracellular expression of antibody fragments directed against HIV reverse transcriptase prevents IIW infection in vitro. Nature Medicine (1995) 1:667–673.
   PubMed Web of Science ®Google Scholar
• WINTER G, GRIFFITHS AD, HAWKINS RE, HOOGENBOOMFIR: Making antibodies by phage display technology. Ann. Rev. Immunol. (1994) 12:433–455.
   PubMed Web of Science ®Google Scholar
• PFEIFFER N: Genetic Engineering News (1994) 14(10):1,9.
   Google Scholar
• GREEN LL, HARDY MC, MAYNARD-CURRIE CE, TSUDA H, LOUIE DM, MENDEZ MJ, ABDERRAHIM H, NOGUCHI M, SMITH DH, ZENG Y, DAVID NE, SASAI H, GARZA D, BRENNER DG, HALES JF, MCGUINESS RP, CAPON DJ, KLAPHOLZ S, JAKOBOVITS A: Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs. Nature Genetics (1994) 7:13–21.
   PubMed Web of Science ®Google Scholar
• CONRAD U, FIEDLER U: Expression of engineered anti-bodies in plant cells. Plant Mol. Biol. (1994) 26:1023–1030.
   PubMed Web of Science ®Google Scholar
• GREGG JM, VEDVICK TS, RASCHKE WC: Recent advances in the expression of foreign genes in Picbia pastoris. Bio/Technology (1993) 11:905–910.
   PubMedGoogle Scholar
• RIDDER R, SCHMITZ R, LEGAY F, GRAM H: Generation of rabbit monoclonal antibody fragments from a combi-natorial phage display library and their production in the yeast Picbia pastoris Bio/Technology (1995) 13:255-52. STRUCK M-M: Biopharmaceutical R&D success rates and 260.development times. Bio/Technology (1994) 12:674–677.
   Google Scholar
• LUCKOW VA: Baculovirus systems for the expression of human gene products. Curr. Opin. Biotech. (1993) 4:654-672.John R Adair' & Susan M Bright2, iScotgen Biopharmaceuticals, Inc., Aberdeen Science and Technology Park, Aberdeen, AB22 8GU, UK,
   Google Scholar
• MORROW KJ, Jr.: Genetic Engineering News (1995) 15(9):16–2Celltech Biologics plc, 216 Bath Road, Slough, Berkshire, SL1 4EN, 17.UK.
   Google Scholar
• STRUCK M-M: Biopharmaceutical R&D success rates and development the. Bio/Tech nology (19%) 12: 674677.
   Google Scholar